MRSN · As filed with the SEC
Mersana Therapeutics income statement, by quarter
The statement as Mersana Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 | Q4 2023† 3 months ended Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | 11,009 | 3,056 | 2,754 | 16,361† | 12,598 | 2,293 | 9,245 | 10,701† |
| Operating expenses: | ||||||||
| Research and development | 12,182 | 16,218 | 18,341 | 22,286† | 14,803 | 17,245 | 18,686 | 21,495† |
| General and administrative | 6,303 | 7,415 | 8,925 | 8,886† | 9,864 | 10,503 | 11,560 | 10,134† |
| Restructuring expenses | 191 | 3,940 | — | 0† | 0 | — | — | 499† |
| Total operating expenses | 18,676 | 27,573 | 27,266 | 31,172† | 24,667 | 27,748 | 30,246 | 32,128† |
| Other income (expense): | ||||||||
| Interest income | 516 | 895 | 1,164 | 1,597† | 1,972 | 2,170 | 2,697 | 2,931† |
| Interest expense | — | — | — | — | — | — | (1,002) | (1,048)† |
| Interest expense | (394) | (674) | (775) | (903)† | (986) | (983) | — | (1,048)† |
| Total other income, net | 122 | 221 | 389 | 694† | 986 | 1,187 | 1,695 | 1,883† |
| Loss before income taxes | (7,545) | — | — | (14,117)† | (11,083) | — | — | (19,544)† |
| Income tax expense | 0 | — | — | 0† | (418) | — | — | 0† |
| Net loss | (7,545) | (24,296) | (24,123) | (14,117)† | (11,501) | (24,268) | (19,306) | (19,544)† |
| Other comprehensive loss | ||||||||
| Unrealized gain (loss) on marketable securities, net of tax | 0 | 0 | (10) | (15)† | 96 | 19 | (101) | 10† |
| Comprehensive loss | (7,545) | (24,296) | (24,133) | (14,132)† | (11,405) | (24,249) | (19,407) | (19,534)† |
| Net loss attributable to common stockholders — basic | (7,545) | (24,296) | (24,123) | (14,117)† | (11,501) | (24,268) | (19,306) | (19,544)† |
| Net loss attributable to common stockholders — diluted | (7,545) | (24,296) | (24,123) | (14,117)† | (11,501) | (24,268) | (19,306) | (19,544)† |
| Net loss per share attributable to common stockholders — basic (in dollars per share) | (1.51) | (4.87) | (0.19) | — | (0.09) | (0.20) | (0.16) | — |
| Net loss per share attributable to common stockholders — diluted (in dollars per share) | (1.51) | (4.87) | (0.19) | — | (0.09) | (0.20) | (0.16) | — |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares) | 4,992,639 | 4,986,784 | 124,466,113 | — | 122,721,918 | 122,440,124 | 121,424,953 | — |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares) | 4,992,639 | 4,986,784 | 124,466,113 | — | 122,721,918 | 122,440,124 | 121,424,953 | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.